Endologix (NSDQ:ELGX) said yesterday that its board of directors set the ratio for its reverse stock split at 1-for-10. Beginning today, Endologix’s common stock will trade on the Nasdaq Global Select market on a reverse stock split-adjusted basis, the Irvine, Calif.-based company reported. Following the reverse split, there will be roughly 10.3 million shares of issued […]
Stent Grafts
Endologix misses the mark with Q4, 2018 numbers
Endologix (NSDQ:ELGX) this week posted fourth-quarter and full-year results that missed the consensus forecasts for sales and earnings for both periods. The Irvine, Calif.-based stent graft maker’s losses grew 78.7% to -$26.0 million, or -26¢ per share, on sales growth of -18.6% to $24.0 million for the three months ended Dec. 31, 2018, compared with the […]
Cook Medical wins FDA nod for Zenith aortic dissection repair stent
Cook Medical said today that it won FDA approval for its Zenith Dissection endovascular system intended to treat Type B aortic dissections. The Bloomington, Ind.-based company’s newly cleared system consists of a proximal stent-graft component and bare stent distal component and is intended to prove a less invasive alternative to open surgery for repairing Type B […]
Ascyrus Medical wins CE Mark for aortic dissection stent
Ascyrus Medical said today that it won CE Mark approval in the European Union for its Ascyrus Medical Dissection Stent, or AMDS, intended for treating acute type A aortic dissections. The Boca Raton, Fla.-based company’s AMDS is an arch remodeling hybrid graft designed as an adjunct to surgical reconstruction, and is intended to reduce the […]
Medtronic touts study data for thoracic aortic stent
Medtronic (NYSE:MDT) said that its thoracic stent graft for the treatment of a potentially deadly blunt-force chest injury performed well five years after implantation, according to a new study. The Rescue study of the long-term durability, safety, and efficacy of the Medtronic’s Valiant Captivia thoracic stent graft system for blunt thoracic aortic injury (BTAI) was presented […]
CE Mark suspended for Endologix Nellix stent graft
Endologix (NSDQ:ELGX) said yesterday that the CE Mark approval for its Nellix stent graft system designed for treating abdominal aortic aneurysms was suspended by its notified body, GMED. The move follows a halt to unrestricted sales of the stent grafts and a voluntary recall of all existing inventory that the Irvine, Calif.-based company announced earlier this month. […]
Endologix recalls Nellix stent graft, bans off-label use
Endologix (NSDQ:ELGX) said today that it’s halting the unrestricted sale of its Nellix stent graft for treating abdominal aortic aneurysms and limiting its use to pre-screened patients under a clinical protocol. “We monitor the performance of the Nellix system through clinical trials, our complaint monitoring system, physician interaction and available publications,” CMO Dr. Matt Thompson said […]
Medtronic wins CE Mark for Valiant Navion thoracic stent graft
Medtronic (NYSE:MDT) said today it received CE Mark in the European union for its Valiant Navion thoracic stent graft system intended for use in minimally invasive procedures to repair lesions in the descending aorta. The Fridley, Minn.-based company said that the device is cleared for use in treating thoracic aortic aneurysms, blunt traumatic aortic injuries, penetrating atherosclerotic […]
LeMaitre Vascular puts up $2m for BD’s Cardial
LeMaitre Vascular (NSDQ:LMAT) said today it inked a deal to acquire Becton Dickinson‘s (NYSE:BDX) Cardial subsidiary for approximately $2.3 million (EU €2 million). The Saint-Étienne, France-based subsidiary produces knitted and woven vascular grafts, valvulotomes and surgical glue, and reported approximately $3.3 million (EU €2.9 million) in sales over the past 12 months, Burlington, Mass.-based LeMaitre said. […]
Endologix launches $20m offering
Endologix (NSDQ:ELGX), looking to refinance its debt, said it’s floating $20 million worth of its own shares in a public offering. The Irvine, Calif.-based stent graft maker said the offering also includes a 30-day underwriter’s option worth another $3 million. Endologix said it plans to use the proceeds to pay off $18.3 million worth of 2.25% […]
FDA approves Medtronic’s Valiant Navion thoracic stent graft
Medtronic (NYSE:MDT) said today that it won FDA approval for its Valiant Navion thoracic stent graft system intended for use in the minimally invasive repair of lesions in the descending thoracic aorta. The Fridley, Minn.-based company said that the stent system is now cleared for use in procedures to repair thoracic aortic aneurysms, blunt thoracic […]